دورية أكاديمية
أعرض في EDS

Real-life efficacy and safety of mepolizumab for eosinophilic granulomatosis with polyangiitis

التفاصيل البيبلوغرافية
العنوان: Real-life efficacy and safety of mepolizumab for eosinophilic granulomatosis with polyangiitis
المؤلفون: Giuseppe A. Ramirez, Adriana Cariddi, Silvia Noviello, Corrado Campochiaro, Valentina Canti, Luca Moroni, Mona-Rita Yacoub, Elena M. Baldissera, Enrica P. Bozzolo, Lorenzo Dagna
المصدر: Clinical Immunology Communications, Vol 2, Iss , Pp 23-29 (2022)
بيانات النشر: Elsevier, 2022.
سنة النشر: 2022
المجموعة: LCC:Immunologic diseases. Allergy
مصطلحات موضوعية: Eosinophilic granulomatosis with polyangiitis, Mepolizumab, Asthma, Corticosteroids, Infections, Immunologic diseases. Allergy, RC581-607
الوصف: Little is known about the efficacy and safety of the anti-interleukin 5 monoclonal antibody mepolizumab (MPZ) in patients with eosinophilic granulomatosis with polyangiitis (EGPA) in real-life. We thus evaluated disease activity, damage and disease-related complications in 14 patients with EGPA receiving MPZ for refractory disease for a median time of 16 months in comparison with up to five years before MPZ start. Asthma exacerbation rates, the Birmingham Vasculitis Activity Score and corticosteroid dosage decreased during MPZ (p
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 2772-6134
Relation: http://www.sciencedirect.com/science/article/pii/S2772613422000026; https://doaj.org/toc/2772-6134
DOI: 10.1016/j.clicom.2022.01.002
URL الوصول: https://doaj.org/article/e0ea706924874de9b12c6eb0fe511d8c
رقم الأكسشن: edsdoj.0ea706924874de9b12c6eb0fe511d8c
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:27726134
DOI:10.1016/j.clicom.2022.01.002